Pawan Kumar, MD
Endocrinology, Diabetes & Metabolism · Tulare, CANPI 1972541829
Payments from drug & device makers
Across 99 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$313
- Mannkind Corporation$190
- Corcept Therapeutics$171
- GSK$141
- Novo Nordisk$136
- Genentech USA, Inc.$125
- plus $972 from 26 others
What the payments were for
- Food & beverage$2,00698%
- Education$432%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 19 | $313 |
| Mannkind Corporation | 10 | $190 |
| Corcept Therapeutics | 7 | $171 |
| GSK | 3 | $141 |
| Novo Nordisk | 8 | $136 |
| Genentech USA, Inc. | 1 | $125 |
| AstraZeneca | 7 | $123 |
| AbbVie | 7 | $116 |
| Merck | 6 | $109 |
| Boehringer Ingelheim | 4 | $86 |
| Insulet Corporation | 3 | $57 |
| Amgen | 2 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| Exact Sciences | 2 | $37 |
| Ascendis Pharma Endocrinology Inc | 1 | $31 |
| Recordati_rare_diseases_inc. | 1 | $29 |
| Amryt Pharma Holdings Ltd | 1 | $25 |
| Tandem Diabetes Care, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Shield Therapeutics Inc | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $19 |
| Gilead | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Viiv Healthcare Company | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$110
How this compares
$2,048 in reported general payments places this provider in the 55th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 114 | $120,309 |
| OzempicSemaglutide | 112 | $107,673 |
| TradjentaLinagliptin | 112 | $79,598 |
| JardianceEmpagliflozin | 81 | $68,413 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 64 | $44,782 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 62 | $38,133 |
| Xigduo XrDapaglifloz Propaned/Metformin | 49 | $33,993 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 48 | $28,258 |
| JanuviaSitagliptin Phosphate | 42 | $25,970 |
| Cinacalcet Hcl | 49 | $25,889 |
| FarxigaDapagliflozin Propanediol | 28 | $22,541 |
| Jentadueto XrLinagliptin/Metformin Hcl | 35 | $19,441 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $7,650 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $7,280 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $7,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance, Synjardy Xr, Jentadueto Xr, Synjardy | $86 | $219,288304 claims |
| Lilly USA, LLCTrulicity | $313 | $120,309114 claims |
| Novo NordiskOzempic, Levemir | $136 | $111,699124 claims |
| MerckJanumet Xr, Januvia | $109 | $54,22790 claims |
| AstraZenecaFarxiga | $123 | $22,54128 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $12 | $7,28011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Tulare
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.